Buchumschlag

Long-term treatment outcomes with a single 0.19 mg fluocinolone acetonide implant in non-infectious uveitis: a real-world study

To evaluate time to first additional treatment following intravitreal 0.19 mg fluocinolone acetonide (FAc) in non-infectious uveitis with posterior segment involvement (NIU-PS) in a real-world setting. Prospective observational study on 37 eyes (30 patients) with chronic or recurrent NIU-PS, treated...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Darwisch, Warda (VerfasserIn) , Waizel, Maria della Volpe (VerfasserIn) , Finger, Robert P. (VerfasserIn) , Januschowski, Kai (VerfasserIn) , Seitz, Berthold (VerfasserIn) , Fries, Fabian Norbert (VerfasserIn) , Rickmann, Annekatrin (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 13 Mar 2025
In: Ocular immunology and inflammation
Year: 2025, Jahrgang: 33, Heft: 6, Pages: 941-947
ISSN:1744-5078
DOI:10.1080/09273948.2025.2478207
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1080/09273948.2025.2478207
Verlag, lizenzpflichtig, Volltext: https://www.tandfonline.com/doi/full/10.1080/09273948.2025.2478207
Volltext
Verfasserangaben:Warda Darwisch, MD, Maria della Volpe Waizel, MD, Robert Patrick Finger, MD, PhD, Kai Januschowski, MD, Berthold Seitz, MD, Fabian Norbert Fries, MD & Annekatrin Rickmann, MD

MARC

LEADER 00000caa a22000002c 4500
001 193159032X
003 DE-627
005 20250812115054.0
007 cr uuu---uuuuu
008 250723s2025 xx |||||o 00| ||eng c
024 7 |a 10.1080/09273948.2025.2478207  |2 doi 
035 |a (DE-627)193159032X 
035 |a (DE-599)KXP193159032X 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Darwisch, Warda  |d 1995-  |e VerfasserIn  |0 (DE-588)1224891694  |0 (DE-627)1744377146  |4 aut 
245 1 0 |a Long-term treatment outcomes with a single 0.19 mg fluocinolone acetonide implant in non-infectious uveitis  |b a real-world study  |c Warda Darwisch, MD, Maria della Volpe Waizel, MD, Robert Patrick Finger, MD, PhD, Kai Januschowski, MD, Berthold Seitz, MD, Fabian Norbert Fries, MD & Annekatrin Rickmann, MD 
264 1 |c 13 Mar 2025 
300 |a 7 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 12.08.2025 
520 |a To evaluate time to first additional treatment following intravitreal 0.19 mg fluocinolone acetonide (FAc) in non-infectious uveitis with posterior segment involvement (NIU-PS) in a real-world setting. Prospective observational study on 37 eyes (30 patients) with chronic or recurrent NIU-PS, treated with FAc after achieving control - indicated by absence of vitreous haze or clearly visible posterior pole. Over a median follow-up of 48.0 ± 0.0 months, we assessed time to and number of additional treatments, inflammatory activity, central subfield macular thickness (CSMT), visual acuity (VA) and intraocular pressure (IOP). Restricted mean time to first adjuvant treatment was 31.9 ± 2.97 months, with 52.8% requiring no additional treatment ≥ 48 months. VA remained stable (baseline 0.56 ± 0.44 logMAR, p = 0.86). A negative correlation was found between the number of prior steroid implants (DEX-I) and time to additional treatment (r = −0.44, p = 0.001). For up to 24 months, FAc reduced anterior chamber flare (0.44 ± 0.81 to 0.00 ± 0.00, p < 0.001), vitreous haze (0.28 ± 0.51 to 0.00 ± 0.00, p = 0.01), and CSMT (407.1 ± 135.9 µm at baseline to 324.2 ± 75.7 µm at M24, p = 0.001). Within 48 months, ocular hypertension (≥25 mmHg) occurred in 22.2% of eyes (8/36), with 19.4% (7/36) requiring new-onset IOP-lowering drops. FAc demonstrated efficacy in managing low-grade NIU-PS, reducing the need for additional treatments and controlling intraocular inflammation for an average of 32 months. 
650 4 |a Fluocinolone 
650 4 |a inflammation 
650 4 |a steroid 
650 4 |a uveitis 
700 1 |a Waizel, Maria della Volpe  |e VerfasserIn  |4 aut 
700 1 |a Finger, Robert P.  |d 1979-  |e VerfasserIn  |0 (DE-588)133279049  |0 (DE-627)539656488  |0 (DE-576)287511855  |4 aut 
700 1 |a Januschowski, Kai  |e VerfasserIn  |4 aut 
700 1 |a Seitz, Berthold  |e VerfasserIn  |4 aut 
700 1 |a Fries, Fabian Norbert  |e VerfasserIn  |4 aut 
700 1 |a Rickmann, Annekatrin  |e VerfasserIn  |4 aut 
773 0 8 |i Enthalten in  |t Ocular immunology and inflammation  |d Abingdon : Taylor & Francis Group, 1993  |g 33(2025), 6, Seite 941-947  |h Online-Ressource  |w (DE-627)300595034  |w (DE-600)1483057-7  |w (DE-576)273877720  |x 1744-5078  |7 nnas  |a Long-term treatment outcomes with a single 0.19 mg fluocinolone acetonide implant in non-infectious uveitis a real-world study 
773 1 8 |g volume:33  |g year:2025  |g number:6  |g pages:941-947  |g extent:7  |a Long-term treatment outcomes with a single 0.19 mg fluocinolone acetonide implant in non-infectious uveitis a real-world study 
856 4 0 |u https://doi.org/10.1080/09273948.2025.2478207  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
856 4 0 |u https://www.tandfonline.com/doi/full/10.1080/09273948.2025.2478207  |x Verlag  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20250723 
993 |a Article 
994 |a 2025 
998 |g 133279049  |a Finger, Robert P.  |m 133279049:Finger, Robert P.  |d 60000  |d 61700  |e 60000PF133279049  |e 61700PF133279049  |k 0/60000/  |k 1/60000/61700/  |p 3 
998 |g 1224891694  |a Darwisch, Warda  |m 1224891694:Darwisch, Warda  |d 60000  |e 60000PD1224891694  |k 0/60000/  |p 1  |x j 
999 |a KXP-PPN193159032X  |e 4749085022 
BIB |a Y 
SER |a journal 
JSO |a {"title":[{"subtitle":"a real-world study","title_sort":"Long-term treatment outcomes with a single 0.19 mg fluocinolone acetonide implant in non-infectious uveitis","title":"Long-term treatment outcomes with a single 0.19 mg fluocinolone acetonide implant in non-infectious uveitis"}],"note":["Gesehen am 12.08.2025"],"origin":[{"dateIssuedDisp":"13 Mar 2025","dateIssuedKey":"2025"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"physDesc":[{"extent":"7 S."}],"name":{"displayForm":["Warda Darwisch, MD, Maria della Volpe Waizel, MD, Robert Patrick Finger, MD, PhD, Kai Januschowski, MD, Berthold Seitz, MD, Fabian Norbert Fries, MD & Annekatrin Rickmann, MD"]},"recId":"193159032X","relHost":[{"language":["eng"],"part":{"volume":"33","extent":"7","issue":"6","text":"33(2025), 6, Seite 941-947","year":"2025","pages":"941-947"},"pubHistory":["1.1993 -"],"note":["Gesehen am 08.09.15"],"origin":[{"publisherPlace":"Abingdon ; New York, NY [u.a.]","dateIssuedDisp":"1993-","publisher":"Taylor & Francis Group ; Informa Healthcare","dateIssuedKey":"1993"}],"title":[{"title":"Ocular immunology and inflammation","title_sort":"Ocular immunology and inflammation"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"disp":"Long-term treatment outcomes with a single 0.19 mg fluocinolone acetonide implant in non-infectious uveitis a real-world studyOcular immunology and inflammation","recId":"300595034","physDesc":[{"extent":"Online-Ressource"}],"id":{"eki":["300595034"],"zdb":["1483057-7"],"issn":["1744-5078"]}}],"id":{"eki":["193159032X"],"doi":["10.1080/09273948.2025.2478207"]},"person":[{"role":"aut","given":"Warda","display":"Darwisch, Warda","family":"Darwisch"},{"family":"Waizel","display":"Waizel, Maria della Volpe","given":"Maria della Volpe","role":"aut"},{"given":"Robert P.","role":"aut","family":"Finger","display":"Finger, Robert P."},{"role":"aut","given":"Kai","display":"Januschowski, Kai","family":"Januschowski"},{"family":"Seitz","display":"Seitz, Berthold","role":"aut","given":"Berthold"},{"display":"Fries, Fabian Norbert","family":"Fries","given":"Fabian Norbert","role":"aut"},{"role":"aut","given":"Annekatrin","display":"Rickmann, Annekatrin","family":"Rickmann"}],"language":["eng"]} 
SRT |a DARWISCHWALONGTERMTR1320 

Ähnliche Einträge